Ascentage Pharma Group International (AAPG) Operating Leases (2022 - 2025)
Ascentage Pharma Group International (AAPG) has disclosed Operating Leases for 4 consecutive years, with $3.1 million as the latest value for Q4 2025.
- For Q4 2025, Operating Leases fell 25.64% year-over-year to $3.1 million; the TTM value through Dec 2025 reached $3.1 million, down 25.64%, while the annual FY2025 figure was $3.2 million, 26.58% down from the prior year.
- Operating Leases hit $3.1 million in Q4 2025 for Ascentage Pharma Group International, down from $4.2 million in the prior quarter.
- Across five years, Operating Leases topped out at $4.2 million in Q4 2024 and bottomed at $2.4 million in Q4 2022.
- Average Operating Leases over 4 years is $3.2 million, with a median of $3.1 million recorded in 2025.
- Year-over-year, Operating Leases soared 33.61% in 2024 and then dropped 25.64% in 2025.
- Ascentage Pharma Group International's Operating Leases stood at $2.4 million in 2022, then surged by 30.09% to $3.2 million in 2023, then surged by 33.61% to $4.2 million in 2024, then decreased by 25.64% to $3.1 million in 2025.
- According to Business Quant data, Operating Leases over the past three periods came in at $3.1 million, $4.2 million, and $3.2 million for Q4 2025, Q4 2024, and Q4 2023 respectively.